Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of 4CMenB (Bexsero) in Adults
NCT02398396Completed
- Sponsor
- University of Oxford
- Start
- Apr 2015
- Primary completion
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of meningococcal group B vaccine in meningococcal group B infection (MenB), sponsored by University of Oxford. Primary endpoint: Breadth of protective activity of serum anti-FHbp antibody responses at 3 months. Started Apr 2015; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal group B infection (MenB)
Beyond the preview
Go deeper on NCT02398396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398396.